🟢 Compass Pathways is trading 7.4% up today after key FDA milestones for its psilocybin therapy

Compass Pathways is trading 7.4% up at $14.30 following significant regulatory progress for its COMP360 psilocybin therapy.

• The FDA accepted an Investigational New Drug (IND) application for a Phase 2b/3 trial targeting Post-Traumatic Stress Disorder (PTSD) on January 7, 2026.
• The agency granted a rolling New Drug Application (NDA) submission and review, plus a Commissioner's National Priority Voucher, for COMP360 in treatment-resistant depression on April 24, 2026.
• These developments signal advanced regulatory momentum and potential commercial readiness for the company's lead candidate, with a launch anticipated in the first half of 2027.